Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

roche.com

Roche Media News

Get the latest updates from Roche Media News directly as they happen.

Follow now 329 followers

Latest posts

Last updated 10 days ago

FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer

10 days ago

Filing acceptance based on phase III data showing giredestrant plus everolimus reduced...

Change to the Roche Enlarged Corporate Executive Committee

13 days ago

Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

22 days ago

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met...

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth

about 1 month ago

Group sales grew by 7%1 at constant exchange rates (CER; 2% in...

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity

about 1 month ago

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight...

FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma

2 months ago

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability...

Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu

3 months ago

With this approval, Roche’s automated mass spectrometry platform now offers the industry’s...

Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

3 months ago

Giredestrant is the only oral SERD to show superior invasive disease-free survival...

European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis

3 months ago

Approval based on phase II NOBILITY and phase III REGENCY studies showing...

Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas

3 months ago

Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed...